Kymera expects topline data from KT-621 Phase 2b AD trial by year-end 2026
Company plans to initiate KT-621 Phase 3 AD trials by mid-2027
Data from KT-621 Phase 2b asthma trial expected in late 2027
Overview
US biopharma firm's Q2 collaboration revenue rose sharply, beating analyst expectations
Net loss for Q2 narrowed compared to prior year
Company ended Q2 with $1.5 bln in cash, runway into 2029
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
Beat
$65 mln
$31.17 mln (20 Analysts)
Q2 Loss Per Share
$0.62
Q2 Net Loss
$61.21 mln
Q2 Operating Expenses
$140.61 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kymera Therapeutics, Inc. is $128.00, about 22.6% above its August 4 closing price of $104.39
Milestone payments - Q2 collaboration revenue was driven by a $45 mln option exercise fee from Gilead and a $20 mln milestone payment from Sanofi
R&D investment - Higher research and development expenses were primarily due to increased investment in the STAT6 program and growth in the R&D organization
KYMR•
